This Week in Biotech Motley Fool The end of the week also brought good news for Biogen Idec (NASDAQ: BIIB ) investors -- as if you haven't been riding high already from the approval of Tecfidera -- when the company announced positive midstage results for Daclizumab for the treatment ... |